Welcome to our dedicated page for METLIFE SEC filings (Ticker: MET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on METLIFE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into METLIFE's regulatory disclosures and financial reporting.
MetLife, Inc. reported consolidated revenues of $38,228 million and net income of $1,941 million for the six months ended June 30, 2026, with diluted EPS of $2.83, compared with $2.32 a year earlier. Total assets were $759,372 million and total equity was $27,741 million at June 30, 2026.
Total consolidated adjusted earnings were $3,235 million for the first half, led by Group Benefits ($942 million), Asia ($907 million) and RIS ($828 million). The company highlighted a strategic reorganization that elevated MetLife Investment Management to a reportable segment and completed the PineBridge Investments acquisition for $885 million. A pending sale of MetLife Ukraine resulted in a $65 million impairment loss, net of income tax, recorded in net investment gains (losses). Operating cash flow was $4,915 million, and policyholder account balances were $245,458 million.
MetLife, Inc. reported second quarter 2026 results and its board approved a new $3.0 billion common stock repurchase authorization.
Net income was $705 million, or $1.09 per share, up 6% per share from a year earlier. Adjusted earnings rose 15% to $1.6 billion, with adjusted EPS up 20% to $2.43. Premiums, fees and other revenues grew 7% to $13.7 billion, and net investment income increased 18% to $6.7 billion. Adjusted return on equity reached 17.0% for the second straight quarter. Book value per share was $38.59, with adjusted book value per share of $57.71.
All operating segments contributed, including Group Benefits adjusted earnings of $503 million (up 25%), Retirement and Income Solutions $377 million (up 2%), Asia $420 million (up 21%), Latin America $268 million (up 15%), and EMEA $108 million (up 8%). MetLife Investment Management reported adjusted earnings of $57 million and total assets under management of $748.1 billion, up 20%. The company returned over $1.1 billion to shareholders through share repurchases and common dividends in the quarter, while holding company cash and liquid assets totaled $3.4 billion.
MetLife, Inc. released preliminary figures for its variable investment income for the quarter ended June 30, 2026. The company currently estimates this income will be between $220 million and $270 million (pre-tax), which it contrasts with its full-year 2026 variable investment income guidance of approximately $1.6 billion (pre-tax).
Variable investment income reflects returns from private equity, real estate and other funds, as well as prepayment fees. MetLife emphasizes that these numbers are unaudited, based on information available to management as of the disclosure date, and may differ materially once full closing procedures are complete. The company cautions readers not to rely on these estimates as a substitute for full U.S. GAAP financial statements or to infer performance for future periods.
MetLife (proposed sales reported on Form 144) — Multiple affiliated accounts reported proposed sales of Common Stock via Form 144. The excerpt lists specific proposed sale entries with dates and amounts, including 121 shares for 04/02/2026 ($8,557.12), 144 shares for 05/05/2026 ($11,505.60), and other transactions through 06/18/2026.
The transactions are attributed to named accounts such as Separate Account, Separate Account II, Separate Account SPI, and MetLife 401k Plan Trust-Large Cap Equity Index. The filing lists broker and trade details for earlier sales and indicates cash sales in the past three months. This Form 144 disclosure notifies the market of proposed resale activity by related accounts.
MetLife, Inc. shareholders held their annual meeting on June 16, 2026. Investors elected eleven directors to terms expiring at the 2027 annual meeting, with each nominee receiving a large majority of votes cast. Shareholders also ratified Deloitte & Touche LLP as MetLife’s independent auditor for 2026.
In addition, shareholders approved on an advisory (non-binding) basis the compensation paid to MetLife’s Named Executive Officers, as described in the 2026 proxy statement. Overall, the voting results indicate broad shareholder support for the company’s board, executive pay program, and external auditor.
MetLife submissions list multiple Rule 144 notices for proposed sales of Common Stock by several MetLife-related accounts. The excerpt shows individual sale entries with transaction dates such as 03/20/2026, 04/02/2026, 05/05/2026, and 05/28/2026 and specific share quantities per entry.
MetLife submitted a Form 144 reporting proposed sales of Common Stock by multiple MetLife-related accounts. The filing lists transactions dated 03/20/2026, 04/02/2026, 05/05/2026, 05/28/2026 and shows representative share counts such as 145 shares, 120 shares and 121 shares. The filing is dated 06/18/2026 and references the NYSE.
MetLife Inc director Christian Stephane Mumenthaler received an award of 587 shares of MetLife common stock on June 16, 2026, valued at $87.40 per share. This grant is part of non-management director retainer fees and was elected to be deferred under MetLife’s Deferred Compensation Plan for Non-Management Directors.
Following this compensation-related acquisition, Mumenthaler directly holds 3,452 shares of MetLife common stock credited to his account.
Kennard William E reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director William E. Kennard received a grant of 587 shares of common stock as non-management director compensation. The award was valued at $87.40 per share and increased his direct holdings to 47,410 shares. He elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. The filing also shows 10 shares of common stock held indirectly through the MetLife Policyholder Trust.
MetLife Inc. director Jeh C. Johnson reported an acquisition of 587 shares of MetLife common stock on June 16, 2026 as a grant or award. These shares represent a portion of his non-management director retainer that is paid in stock and deferred under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this grant, he directly holds 9,498 shares.